Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026 at 09:58 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

2149611199 1 1 Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

The Company’s Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia–(April 20, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug … Continue reading

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	264.14	-3.08 (-1.15%)
AAPL	300.23	+2.02 (0.68%)
AMD	424.10	-25.60 (-5.69%)
BAC	49.77	-0.08 (-0.16%)
GOOG	393.32	-3.85 (-0.97%)
META	614.23	-4.20 (-0.68%)
MSFT	421.92	+12.49 (3.05%)
NVDA	225.32	-10.42 (-4.42%)
ORCL	192.95	-2.66 (-1.36%)
TSLA	422.24	-21.06 (-4.75%)

Symbol

Price

Change (%)

AMZN

264.14

-3.08 (-1.15%)

AAPL

300.23

+2.02 (0.68%)

AMD

424.10

-25.60 (-5.69%)

BAC

49.77

-0.08 (-0.16%)

GOOG

393.32

-3.85 (-0.97%)

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

More News

Recent Quotes